Cascade Bio has developed a groundbreaking enzyme stabilization technology called Body Armor for Enzymes, which extends enzyme lifespan from hours to several months by protecting enzymes from degradation using scalable, affordable materials.

This technology significantly enhances enzyme stability, allowing enzymes to maintain activity for months under industrial conditions, a major improvement over previous lifespans of only hours.

Early collaborations demonstrate that stabilized enzymes can operate for months, greatly improving costs and ease of use in various industrial applications.

Based in Denver with operations in California and New York, Cascade Bio has raised $6 million in funding to advance its enzyme-based, cell-free biomanufacturing processes, aiming to replace traditional petrochemical methods.

The funding includes a $2.8 million seed round led by Endurance28, along with $3.2 million in nondilutive grants from the U.S. NSF, supporting the company's development efforts.

The funding round was participated in by Stray Dog Capital, 1Flourish, Range Ventures, 10VC, and Amplify, highlighting strong investor confidence in Cascade Bio's vision.

Founded by Alex Rosay and James Weltz, with backgrounds in chemical engineering and experience at Zymergen, Stanford, and CU Boulder, the company is strategically positioned to lead in industrial biotechnology.

Cascade Bio aims to be a leader in enzyme immobilization technology, with a mission to make chemical production faster, cleaner, and more sustainable.

Investors, including Endurance28, praise the company's scientific rigor and ambitious vision, positioning it as a key player in the biomanufacturing revolution.

The company's platform has successfully stabilized over thirty different enzymes, increasing their durability and enabling integration into sectors like chemicals, pharmaceuticals, and food manufacturing.

Cascade Bio has collaborated with more than 20 industrial customers, achieving a 100% success rate in improving enzyme stability across various applications.

CEO Alex Rosay emphasizes that their technology can extend enzyme activity from hours to months, promising a transformative impact on biocatalysis costs and usability.